Agammaglobulinaemia Tyrosine Kinase

A non-receptor tyrosine kinase that is essential for the development, maturation, and signaling of B-LYMPHOCYTES. It contains an N-terminal zinc finger motif and localizes primarily to the PLASMA MEMBRANE and nucleus of B-lymphocytes. Mutations in the gene that encode this kinase are associated with X-LINKED AGAMMAGLOBULINEMIA.

Also Known As:

Networked: 1519 relevant articles (106 outcomes, 111 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Byrd, John C: 42 articles (01/2022 - 06/2011)
2.	Burger, Jan A: 30 articles (01/2022 - 02/2012)
3.	Brown, Jennifer R: 27 articles (01/2022 - 03/2013)
4.	Woyach, Jennifer A: 25 articles (01/2022 - 10/2013)
5.	O'Brien, Susan: 23 articles (01/2022 - 02/2012)
6.	Wierda, William G: 23 articles (01/2022 - 02/2012)
7.	Wiestner, Adrian: 22 articles (11/2021 - 01/2013)
8.	Furman, Richard R: 20 articles (01/2022 - 01/2013)
9.	Wang, Michael: 19 articles (10/2022 - 09/2014)
10.	Hillmen, Peter: 18 articles (01/2022 - 01/2016)

Related Diseases

1.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/25/2022 - "The covalent Bruton's tyrosine kinase inhibitors (BTKis) are highly effective for the treatment of chronic lymphocytic leukemia (CLL). " 01/01/2020 - "Therapeutic targeting of Bruton tyrosine kinase (BTK) has dramatically improved survival outcomes for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). " 10/01/2017 - "Purpose: Targeting the B-cell receptor (BCR) pathway with inhibitors of Bruton tyrosine kinase (BTK) and PI3Kδ is highly effective for the treatment of chronic lymphocytic leukemia (CLL). " 01/01/2021 - "B-cell receptor signalling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia (CLL). " 01/01/2023 - "The efficacy of Bruton tyrosine kinase inhibitors (BTKi) remains suboptimal in chronic lymphocytic leukemia (CLL) treatment. "
2.	Neoplasms (Cancer) 01/01/2020 - "Pharmacological inhibitors of Bruton tyrosine kinase (BTK) have revolutionized treatment of B-lymphocyte malignancies and show great promise for dampening autoimmunity. " 01/01/2018 - "PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells." 10/01/2021 - "Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies." 01/28/2016 - "We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell malignancies. " 01/01/2024 - "Drug resistance to Bruton's Tyrosine Kinase (BTK) inhibitors presents a challenge in treating B-cell malignancies, and the mechanism behind drug resistance remains unclear. "
3.	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/01/2019 - "Bruton's tyrosine kinase (BTK) is a key mediator of BCR-dependent cell growth signaling and a clinically effective therapeutic target in mantle cell lymphoma (MCL). " 01/01/2023 - "Commentary on: Hess et al. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. " 01/01/2023 - "Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study." 11/02/2023 - "Bruton's tyrosine kinase inhibitors (BTKi) and CAR T-cell therapy have demonstrated tremendous clinical benefits in mantle cell lymphoma (MCL) patients, but intrinsic or acquired resistance inevitably develops. " 11/01/2023 - "Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. "
4.	B-Cell Lymphoma (Lymphoma, B Cell) 01/01/2021 - "Clinical trials investigating novel agents such as Bruton tyrosine kinase and B-cell lymphoma 2 inhibitors in this specific clinical setting are warranted." 10/01/2023 - "Bruton's tyrosine kinase inhibitor (BTKi) has revolutionized the treatment of B-cell lymphomas. " 05/23/2023 - "Both B-cell lymphoma 2 (BCL2) and Bruton tyrosine kinase (BTK) inhibitors are highly effective agents for CLL treatment. " 05/03/2023 - "The development of inhibitors of Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL2) has resulted in a paradigm shift in the treatment of chronic lymphocytic leukaemia (CLL) over the last decade. " 01/01/2023 - "B-cell lymphomas that harbor the MYD88L265P mutation form a complex with phosphorylated Bruton's tyrosine kinase (BTK) and are responsive to BTK inhibition. "
5.	Lymphoma (Lymphomas) 11/08/2022 - "Targeting Bruton's tyrosine kinase in vitreoretinal lymphoma: an open-label, prospective, single-center, phase 2 study." 12/03/2023 - "A literature search was conducted through PubMed MEDLINE, ClinicalTrials.gov, and the FDA website (January 2018-January 2023) using the following key terms: lymphoma, non-covalent, Bruton's tyrosine kinase (BTK), and relapse. " 12/01/2023 - "Recent insights into the pathophysiology of CNS lymphoma have identified the Bruton's tyrosine kinase (BTK) signaling pathway as a potential target. " 12/01/2023 - "A novel Bruton's tyrosine kinase inhibitor JDB175 shows potent efficacy to suppress central nervous system lymphoma." 11/01/2023 - "Bruton Tyrosine Kinase Inhibitor in 2 Patients With Vitreoretinal Lymphoma."

Related Drugs and Biologics

1.	ibrutinib
2.	venetoclax
3.	acalabrutinib
4.	zanubrutinib
5.	Phosphotransferases (Kinase)
6.	Phosphatidylinositols (Phosphatidylinositol)
7.	evobrutinib
8.	Immune Checkpoint Inhibitors
9.	Proteasome Inhibitors
10.	Immunologic Factors (Immunomodulators)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
4.	Immunotherapy
5.	Oral Administration